What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
It combines glutathione with additional vitamins and antioxidants to enhance the skin-brightening effects, reduce pigmentation, and improve overall skin health
BMC Syst Biol 7:103 Liu B, Teschemacher AG, Kasparov S (2017) Astroglia as a cellular target for neuroprotection and treatment of neuro-psychiatric disorders
Isolation of a new gene GS2 (DXS1283E) from a CpG island between STS and KAL1 on xp22.3
If you're a skincare expert, you've probably already heard of astaxanthin , a powerful natural antioxidant that has gained attention in the dermatology field
Benefits of Glutathione Treatments Glutathione treatments are popular for both wellness and appearance goals